Evaluation of Cardiac Monitoring in Patients following a Stroke
Mary Kalafut, M.D.
Study participants are randomized to receive either the Reveal LINQ implantable cardiac monitor (inserted within 10 days of the qualifying stroke) or the usual standard of care for ischemic stroke. This study requires participants to return for follow-up clinic visits at 1 month (post hospital discharge) then every 3 months for 1 year. After 1 year, follow-up is required every 6 months for approximately 3 years.
Have had an ischemic stroke of presumed known origin within 10 days of study enrollment
Be willing and able to undergo all study requirements and complete the study required follow-up
Be 60 years of age or older, or age 50 to 59 with a documented medical history of at least one additional risk factor for stroke
Meet all other eligibility criteria
Have had a stroke of unknown origin or had a cardioembolic stroke
Have untreated hyperthyroidism
Have had a recent heart attack or cardiac surgery
Have a mechanical heart valve
Have valvular disease requiring immediate surgical intervention.
Have documented atrial fibrillation or atrial flutter.
Have an indication for oral anticoagulation.
Be enrolled in a another clinical trial
American Heart Association guidelines recommend cardiac monitoring with a Holter monitor for up to 30 days after a patient has a stroke to watch for signs of atrial fibrillation (a-fib). Previous research has suggested that monitoring for a longer period of time is better at detecting symptoms of a-fib in more patients.
Insertable cardiac monitors like the Reveal LINQ Cardiac monitor continuous monitor heart rhythms and can detect infrequent episodes of a-fib for up to 3 years.